Full Text Full Text (PDF) Data Supplement Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Nuechterlein, K. H. Articles by Marder, S. R. Search for Related Content PubMed Citation Articles by Nuechterlein, K. H. Articles by Marder, S. R. Schizophrenia Spectrum Disorders Cognition Related Articles

The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

OBJECTIVE: The lack of an accepted standard for measuring cognitive change in schizophrenia has been a major obstacle to regulatory approval of cognition-enhancing treatments. A primary mandate of the National Institute of Mental Health’s Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) initiative was to develop a consensus cognitive battery for clinical trials of cognition-enhancing treatments for schizophrenia through a broadly based scientific evaluation of measures. METHOD: The MATRICS Neurocognition Committee evaluated more than 90 tests in seven cognitive domains to identify the 36 most promising measures. A separate expert panel evaluated the degree to which each test met specific selection criteria. Twenty tests were selected as a beta battery. The beta battery was administered to 176 individuals with schizophrenia and readministered to 167 of them 4 weeks later so that the 20 tests could be compared directly. RESULTS: The expert panel ratings are presented for the initially selected 36 tests. For the beta battery tests, data on test-retest reliability, practice effects, relationships to functional status, practicality, and tolerability are presented. Based on these data, 10 tests were selected to represent seven cognitive domains in the MATRICS Consensus Cognitive Battery. CONCLUSIONS: The structured consensus method was a feasible and fair mechanism for choosing candidate tests, and direct comparison of beta battery tests in a common sample allowed selection of a final consensus battery. The MATRICS Consensus Cognitive Battery is expected to be the standard tool for assessing cognitive change in clinical trials of cognition-enhancing drugs for schizophrenia. It may also aid evaluation of cognitive remediation strategies.

Related Articles:

Pharmacological Treatment of Cognition in Schizophrenia: An Idea Whose Method Has Come

Philip D. Harvey and Barbara A. Cornblatt
Am J Psychiatry 2008 165: 163-165. [Full Text] [PDF]

This article has been cited by other articles:

				D. M. Barch and R. S.E. Keefe Anticipating DSM-V: Opportunities and Challenges for Cognition and Psychosis Schizophr Bull, November 18, 2009; (2009) sbp139v1. [Full Text] [PDF]

				S. M. Eack, D. P. Greenwald, S. S. Hogarty, S. J. Cooley, A. L. DiBarry, D. M. Montrose, and M. S. Keshavan Cognitive Enhancement Therapy for Early-Course Schizophrenia: Effects of a Two-Year Randomized Controlled Trial Psychiatr Serv, November 1, 2009; 60(11): 1468 - 1476. [Abstract] [Full Text] [PDF]

				E. Bora, M. Yucel, and C. Pantelis Cognitive Impairment in Affective Psychoses: A Meta-analysis Schizophr Bull, September 18, 2009; (2009) sbp093v1. [Abstract] [Full Text] [PDF]

				M. F. Green New Possibilities in Cognition Enhancement for Schizophrenia Am J Psychiatry, July 1, 2009; 166(7): 749 - 752. [Full Text] [PDF]

				F. R. Leifker, T. L. Patterson, R. K. Heaton, and P. D. Harvey Validating Measures of Real-World Outcome: The Results of the VALERO Expert Survey and RAND Panel Schizophr Bull, June 12, 2009; (2009) sbp044v1. [Abstract] [Full Text] [PDF]

				K. E. Stephan, K. J. Friston, and C. D. Frith Dysconnection in Schizophrenia: From Abnormal Synaptic Plasticity to Failures of Self-monitoring Schizophr Bull, May 1, 2009; 35(3): 509 - 527. [Abstract] [Full Text] [PDF]

				F. J. Frese III, E. L. Knight, and E. Saks Recovery From Schizophrenia: With Views of Psychiatrists, Psychologists, and Others Diagnosed With This Disorder Schizophr Bull, March 1, 2009; 35(2): 370 - 380. [Abstract] [Full Text] [PDF]

				A. Holmen, M. Juuhl-Langseth, R. Thormodsen, I. Melle, and B. R. Rund Neuropsychological Profile in Early-Onset Schizophrenia-Spectrum Disorders: Measured With the MATRICS Battery Schizophr Bull, February 17, 2009; (2009) sbn174v1. [Abstract] [Full Text] [PDF]

				J. D. Ragland, R. Cools, M. Frank, D. A. Pizzagalli, A. Preston, C. Ranganath, and A. D. Wagner CNTRICS Final Task Selection: Long-Term Memory Schizophr Bull, January 1, 2009; 35(1): 197 - 212. [Abstract] [Full Text] [PDF]

				K. H. Nuechterlein, S. J. Luck, C. Lustig, and M. Sarter CNTRICS Final Task Selection: Control of Attention Schizophr Bull, January 1, 2009; 35(1): 182 - 196. [Abstract] [Full Text] [PDF]

				D. Dickinson Digit symbol coding and general cognitive ability in schizophrenia: worth another look? The British Journal of Psychiatry, November 1, 2008; 193(5): 354 - 356. [Abstract] [Full Text] [PDF]

				R. Freedman, A. Olincy, R. W. Buchanan, J. G. Harris, J. M. Gold, L. Johnson, D. Allensworth, A. Guzman-Bonilla, B. Clement, M. P. Ball, et al. Initial Phase 2 Trial of a Nicotinic Agonist in Schizophrenia Am J Psychiatry, August 1, 2008; 165(8): 1040 - 1047. [Abstract] [Full Text] [PDF]

				R. W. Heinrichs, N. Ammari, A. A. Miles, and S. McDermid Vaz Cognitive Performance and Functional Competence as Predictors of Community Independence in Schizophrenia Schizophr Bull, July 30, 2008; (2008) sbn095v1. [Abstract] [Full Text] [PDF]

				S. M. Eack, C. G. Greeno, M. F. Pogue-Geile, C. E. Newhill, G. E. Hogarty, and M. S. Keshavan Assessing Social-Cognitive Deficits in Schizophrenia With the Mayer-Salovey-Caruso Emotional Intelligence Test Schizophr Bull, July 22, 2008; (2008) sbn091v1. [Abstract] [Full Text] [PDF]

				A. C. Leon Implications of Clinical Trial Design on Sample Size Requirements Schizophr Bull, July 1, 2008; 34(4): 664 - 669. [Abstract] [Full Text] [PDF]

				D. M. Barch, C. S. Carter, and the CNTRICS Executive Committee Measurement Issues in the Use of Cognitive Neuroscience Tasks in Drug Development for Impaired Cognition in Schizophrenia: A Report of the Second Consensus Building Conference of the CNTRICS Initiative Schizophr Bull, July 1, 2008; 34(4): 613 - 618. [Abstract] [Full Text] [PDF]

				S. R. Marder Neurocognition as a Treatment Target in Schizophrenia Focus, April 1, 2008; 6(2): 180 - 183. [Abstract] [Full Text] [PDF]

Get information about faster international access.

Privacy Policy

Copyright © 2008 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us